Welcome to Industry Focus, the podcast that dives into a different sector of the stock market every day.

It's Wednesday, November 8th.

I'm your host, Christine Hargis, and I'm joined via Skype by health care expert Todd Campbell

one a fool.com's most prolific writers.

Todd how's it going?

Good good I've been prolific writing all day.

I introduce you so much on the show that I'm kind of running out of new ways to do it.

We got to mix it up, no question.

Are you prolific, prolific Lee writing on anything interesting today?

Oh yeah, I mean it listeners can go right online

to molly fool.com right type in Todd Campbell and see everything I'm putting

out. Perfect. So for today we have two topics to discuss. The first one is a company called

Kerix Bioformaceuticals, which I don't think we've ever covered on the show before if we have it's escaping my memory

it's certainly not something that we've covered heavily but they have some

interesting things going on and then we're going to talk about Valiant which we

have certainly talked about on this show before and

we'll give you the update with what is going on with this company that is somewhat

of a turnaround story that is just starting to get their footing back. But first, Carix Bio Pharmaceuticals.

The ticker there is K-E-R-X, for those of you.

What a weird story, Christine, on Carix, right?

Yeah.

That's probably why we're interested in talking about it. I mean, so the headline here is that they got a drug approved and they were poor

...